ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

ClinicalTrials.gov ID: NCT03512353

Public ClinicalTrials.gov record NCT03512353. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

Study identification

NCT ID
NCT03512353
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Amgen
Industry
Enrollment
7 participants

Conditions and interventions

Interventions

  • Carfilzomib Drug
  • Dexamethasone Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 4, 2018
Primary completion
Jan 15, 2020
Completion
Jan 15, 2020
Last update posted
Jan 7, 2021

2018 – 2020

United States locations

U.S. sites
31
U.S. states
19
U.S. cities
29
Facility City State ZIP Site status
Research Site Palm Springs California 92262
Research Site Riverside California 92501
Research Site Glenwood Springs Colorado 81601
Research Site Boynton Beach Florida 33426
Research Site Orange City Florida 32763
Research Site Pensacola Florida 32504
Research Site Honolulu Hawaii 96813
Research Site River Forest Illinois 60305
Research Site Tinley Park Illinois 60487
Research Site Indianapolis Indiana 46260
Research Site Paducah Kentucky 42003
Research Site Bethesda Maryland 20817
Research Site Midland Michigan 48640
Research Site Jackson Mississippi 39202
Research Site Lincoln Nebraska 68506
Research Site Florham Park New Jersey 07932
Research Site Charlotte North Carolina 28204
Research Site Charlotte North Carolina 28207
Research Site Hendersonville North Carolina 28792
Research Site Pinehurst North Carolina 28374
Research Site Winston-Salem North Carolina 27103
Research Site Zanesville Ohio 43701
Research Site Charleston South Carolina 29414
Research Site Rock Hill South Carolina 29732
Research Site Corpus Christi Texas 78412
Research Site Fort Worth Texas 76104
Research Site Houston Texas 77057
Research Site Houston Texas 77090
Research Site Ogden Utah 84405
Research Site Fredericksburg Virginia 22408
Research Site Yakima Washington 98902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03512353, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 7, 2021 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03512353 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →